CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Dexcom to Launch G7 15 Day Glucose Monitoring System in Canada in November

By Public Technologies
  • DexCom will launch its G7 15 Day continuous glucose monitoring system in Canada in November for adults with diabetes aged 18 or older.
  • Public reimbursement will begin in November for many eligible people with type 1 and type 2 diabetes across Canada.
  • Most Canadians whose private health plans currently cover continuous glucose monitoring will soon gain access to the new system.
  • The system offers up to 15.5 days of wear, reducing sensor changes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261028811764) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk